# Erythropoiesis-Stimulating Agents and Development of Cancer Among Patients Receiving Dialysis

## TL;DR

A study found that high-dose use of erythropoiesis-stimulating agents in dialysis patients aged 60 or older is linked to a higher risk of developing cancer.

## Contribution

The study provides new evidence linking high-dose erythropoiesis-stimulating agents to increased cancer risk in older dialysis patients.

## Key findings

- High-dose ESA use was associated with increased odds of cancer development (adjusted odds ratio, 1.23).
- The association was stronger in patients aged 60 years or older (adjusted odds ratio, 1.47).
- No significant association was found in patients younger than 60 years.

## Abstract

This case-control study evaluates the association between treatment with erythropoiesis-stimulating agents and cancer risk in patients receiving long-term dialysis.

Is there an association between erythropoiesis-stimulating agents (ESAs) in the management of anemia and cancer risk in patients with kidney failure?

In this case-control study of 9776 patients undergoing dialysis, high-dose ESA use was associated with higher odds of new cancer development among older patients (aged ≥60 years).

These findings suggest caution should be exercised to avoid aiming for excessively high hemoglobin levels during ESA therapy.

Although erythropoiesis-stimulating agents (ESAs) are widely used to treat anemia in patients with kidney failure, concerns have been raised about their potential to promote tumor growth. However, the association between ESA use and incidence of cancer in patients undergoing long-term dialysis remains unclear.

To examine the association between ESA use and cancer development among patients receiving long-term dialysis.

This nested case-control study identified patients in the Korean National Health Insurance Service database with kidney failure who began long-term dialysis treatment and received ESAs between 2006 and 2017 in Korea. Each case with incident cancer was matched with 4 controls based on age, sex, follow-up time, year of dialysis initiation, and dialysis modality. Data were analyzed between August 2024 and August 2025.

ESA exposure was categorized as high or low dose according to the median of the mean weekly dose of each ESA drug.

The primary outcome was newly diagnosed cancer occurring 6 months after the initiation of long-term dialysis. Conditional logistic regression, adjusted for potential confounders, was used to assess the association between ESA use and cancer development.

A total of 9776 patients (mean [SD] age, 62.2 [12.0] years; 6296 [64.4%] male) undergoing dialysis were included; 2320 patients with incident cancer were matched to 7456 controls. After multivariable adjustment, high-dose ESA use was found to be associated with increased odds of cancer development (adjusted odds ratio, 1.23; 95% CI, 1.11-1.35) compared with low-dose use. Stratified by age, the odds of cancer development were 0.90 (95% CI, 0.77-1.05) among patients aged younger than 60 years and 1.47 (95% CI, 1.30-1.67) among those aged 60 years or older.

In this case-control study of patients undergoing dialysis, high-dose ESA use was associated with greater odds of new cancer development. These results suggest that caution should be exercised to avoid aiming for excessively high hemoglobin levels during ESA therapy.